Significance of risk factors correction for treatment and prevention of arterial hypertension in outpatient conditions

Cover Page


Cite item

Full Text

Abstract

Aim. To evaluate the significance of risk factors correction for treatment effectiveness improvement and prevention of arterial hypertension in outpatient conditions.

Methods. The study was conducted in two phases over the period of 2011-2015 in Baku outpatient clinics. At the beginning of the first part of work 547 patients with controlled hypertension were followed up, by the end of study 437 patients remained followed up, 196 men and 241 women, aged from 23 to 68 years, disease duration was from 4 months to 14 years. At the beginning of the second part of the study measures for hypertension prevention were taken in 916 patients with normal blood pressure (788 patients completed the study).

Results. In patients with long-term course of the disease, maintaining a stable target blood pressure (<130/80 mm Hg) was possible with great difficulty, despite the antihypertensive therapy. The main reasons were occasional visits to the doctor, and low compliance to treatment, lack of risk factors awareness and their correction necessity. The antihypertensive therapy combined with risk factors correction resulted in the blood pressure normalization during the entire follow-up period. In the second part of the study, it was shown that the motivation to the risk factors correction prevented the formation of hypertension new cases (in the first group - only 5.1±1.6% of new clinically not apparent hypertension cases which were effectively cured). In the group with a partial motivation of the major risk factors modification 11.4±1.7% of new cases of clinically not apparent hypertension (χ2=6.08; p <0.02) and 2.4±0.8% cases of symptomatic hypertension occurred over the 3 years. In the group of patients, who were not motivated to correct risk factors 18.9±2.4% of new cases of clinically not apparent hypertension (χ2=6.47; p <0.02) and 6.6±1.5% of severe arterial hypertension cases (χ2=6.51; p <0.02) were formed over the 3 years. The lack of motivation reduced the hypertension treatment effectiveness: in the clinically not apparent forms it was 61.2±7.0% (χ2=5.92; p <0.02), and in clinically apparent forms - 29.4±11.4% (χ2=4.81; p <0.02).

Conclusion. Approach to secondary prevention of hypertension at the population level was evaluated, the basis of which consisted of the outpatient network readiness to the continuous blood pressure monitoring, scientific rationale of the dominant risk factors, explanatory work on the risk factors modification and health status self-control among the population; significance of risk factors correction was found.

About the authors

A A Agayev

Azerbaijan Medical University, Baku, Azerbaijan

Author for correspondence.
Email: nauchnayastatya@yandex.ru

References

  1. Агаев А.А. Суммарная оценка доминантных социально-поведенческих факторов риска формирования артериальной гипертонии. Терап. вестн. 2011; (4): 5-7.
  2. Андреева Г.Ф. Сезонная динамика амбулаторных и клинических показателей артериального давления у больных со стабильной артериальной гипертонией (обзор литературы). Профил. мед. 2014; (4): 33-38.
  3. Измайлова О.В., Калинина А.М., Еганян Р.А. Алиментарно-зависимые факторы риска развития артериальной гипертонии и технологии их коррекции (обзор литературы). Профил. мед. 2011; (1): 19-26.
  4. Кобалава Ж.Д., Виллевальде С.В., Исикова Х.В. Повышение приверженности к антигипертензивной терапии у больных артериальной гипертонией с помощью образовательных программ и рационального применения ингибитора ангиотензин-превращающего фермента периндоприла. Результаты исследования ПРИЗМА. Кардиология. 2010; (11): 17-26.
  5. Колбасников С.В., Воробьёва И.О., Кононова Е.С. и др. Факторы риска артериальной гипертензии и психологическая готовность больных на проведение профилактики. Здравоохр. РФ. 2009; (2): 21-23.
  6. Котовская Ю.В., Виллевальде С.В., Тигай Ж.Г., Кобалава Ж.Д. Приверженность, мотивация и осведомлённость больных артериальной гипертонией при лечении фиксированной комбинацией периндоприла А и амлодипина (результаты исследования КОНСТАНТА). Тер. архив. 2015; (2): 64-69.
  7. Мустафаев М.К., Агаев А.А. Контроль холестерина на поликлиническом уровне в профилактике артериальной гипертонии и сердечно-сосудистой заболеваемости. Curierul med. 2011; 4 (322): 8-11.
  8. Стрюк Р.И., Бурлакова Б.Н., Бернс С.А., Потиевский Б.Г. Факторы риска развития артериальной гипертензии и метаболических нарушений у практически здоровых мужчин. Кардиология. 2014; (2): 13-16.
  9. Хамидуллаева Г.А., Нагай А.В., Абдуллаева Г.Ж. и др. Особенности вкусовой солечувствительности у мужчин и женщин, страдающих артериальной гипертензией. Профил. мед. 2014; (3): 50-54.
  10. Graudal N.A., Hubeck-Graudal T., Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, rennin, aldosterone, catecholamines, cholesterol and triglyceride (Cochrane Review). Am. J. Hypertens. 2012; 25: 1-15. http://dx.doi.org/10.1038/ajh.2011.210
  11. Green B.B., Cook A.J., Ralston J.D. et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008; 299: 2857-2867. http://dx.doi.org/10.1001/jama.299.24.2857
  12. Marquez-Contreras E., Casado-Martinez J.J., Ramos-Perez J. et al. Trial on the efficacy of programmes of health education on hypertension therapy compliance. Aten. Primaria. 2008; 21: 199-204.
  13. Modesti P.A., Morabito M., Massetti L. et al. Seasonal blood pressure changes: an independent relationship with temperature and daylight hours. Hypertension. 2013; 61 (4): 908-914. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.00315
  14. Pickering T.G., Miller N.H., Ogedegbe G. et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008; 52: 10-29. http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.189010
  15. Sever P., Dahlof B., Poulter N.R. et al. Prevention of coronary and stork events with artovastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Angl. Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. Lancet. 2003; 361: 1149-1158. http://dx.doi.org/10.1016/S0140-6736(03)12948-0
  16. Szirmal L.A., Arnold C., Farsang C. Improving control of hypertension by an integrated approach - results of the «Manage it well!» programme. J. Hypertens. 2005; 23: 203-211.

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2015 Agayev A.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies